A real life study evaluating efficacy and safety of combination of Carfilzomib, Lenalidomide and Dexamethasone in patients with relapsed and refractory multiple myeloma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use

01 Oct 2022 Results assessing the efficacy and safety of carfilzomib, in combination with lenalidomide-dexamethasone as salvage regimen in patients with refractory multiple myeloma, published in the Clinical Lymphoma, Myeloma & Leukemia.
17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association
04 Jun 2019 Results (n=41) assessing efficacy of Carfilzomib-Lenalidomide-Dexamethasone in multiple myeloma patients, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com